Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $1.05 in the prior trading day, Lucid Diagnostics Inc (NASDAQ: LUCD) closed at $1.1, up 4.76%. In other words, the price has increased by $4.76 from its previous closing price. On the day, 0.66 million shares were traded. LUCD stock price reached its highest trading level at $1.1 during the session, while it also had its lowest trading level at $1.035.
Ratios:
Our goal is to gain a better understanding of LUCD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.15. In the meantime, Its Debt-to-Equity ratio is 3.51 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ascendiant Capital Markets on December 27, 2021, initiated with a Buy rating and assigned the stock a target price of $16.
On November 08, 2021, Needham started tracking the stock assigning a Buy rating and target price of $17.
On November 08, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $21.Cantor Fitzgerald initiated its Overweight rating on November 08, 2021, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 20 ’25 when Matheis Dennis bought 100,000 shares for $1.02 per share. The transaction valued at 101,840 led to the insider holds 665,443 shares of the business.
Matheis Dennis bought 187,098 shares of LUCD for $242,292 on May 20 ’25. The Director now owns 187,098 shares after completing the transaction at $1.29 per share. On May 21 ’25, another insider, Matheis Dennis, who serves as the Director of the company, bought 129,684 shares for $1.32 each. As a result, the insider paid 171,520 and bolstered with 316,782 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUCD now has a Market Capitalization of 112082304 and an Enterprise Value of 161795584. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.37. Its current Enterprise Value per Revenue stands at 37.109 whereas that against EBITDA is -3.438.
Stock Price History:
The Beta on a monthly basis for LUCD is 1.21, which has changed by 0.32530117 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, LUCD has reached a high of $1.80, while it has fallen to a 52-week low of $0.73. The 50-Day Moving Average of the stock is 0.10%, while the 200-Day Moving Average is calculated to be -3.64%.
Shares Statistics:
The stock has traded on average 1.16M shares per day over the past 3-months and 706380 shares per day over the last 10 days, according to various share statistics. A total of 101.83M shares are outstanding, with a floating share count of 40.45M. Insiders hold about 62.71% of the company’s shares, while institutions hold 18.64% stake in the company. Shares short for LUCD as of 1753920000 were 5281264 with a Short Ratio of 4.56, compared to 1751241600 on 4854331. Therefore, it implies a Short% of Shares Outstanding of 5281264 and a Short% of Float of 7.380000000000001.
Earnings Estimates
The current market rating for Lucid Diagnostics Inc (LUCD) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.45 and -$0.46 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.33, with 3.0 analysts recommending between -$0.31 and -$0.37.
Revenue Estimates
5 analysts predict $1.36M in revenue for the current quarter. It ranges from a high estimate of $1.69M to a low estimate of $1.25M. As of the current estimate, Lucid Diagnostics Inc’s year-ago sales were $1.17MFor the next quarter, 5 analysts are estimating revenue of $1.49M. There is a high estimate of $1.94M for the next quarter, whereas the lowest estimate is $1.3M.
A total of 6 analysts have provided revenue estimates for LUCD’s current fiscal year. The highest revenue estimate was $5.62M, while the lowest revenue estimate was $4.54M, resulting in an average revenue estimate of $4.88M. In the same quarter a year ago, actual revenue was $4.35MBased on 6 analysts’ estimates, the company’s revenue will be $12.34M in the next fiscal year. The high estimate is $17M and the low estimate is $9.83M.
